drugset / Trial / NCT01296243
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.
Timeline
- Start
- 2011-02
- Primary completion
- 2012-08
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tesetaxel | Small molecule | 27 mg/m2 | Oral |
| Subject | Tesetaxel | Small molecule | 35 mg/m2 | Oral |